Literature DB >> 23155059

Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining.

Zarir Udwadia, Deepesh Vendoti.   

Abstract

Entities:  

Keywords:  Infection; International Hlth; Tuberculosis

Mesh：

Substances：

Year:  2012        PMID： 23155059     DOI： 10.1136/jech-2012-201640

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN： 0143-005X            Impact factor:   3.710


× No keyword cloud information.
  11 in total

1.  Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.

Authors:  Ji-Chan Jang; Yong-Gyun Jung; Jungil Choi; Hyunju Jung; Sungweon Ryoo
Journal:  J Microbiol       Date:  2017-04-20       Impact factor: 3.422

Review 2.  Genomic insights into tuberculosis.

Authors:  James E Galagan
Journal:  Nat Rev Genet       Date:  2014-03-25       Impact factor: 53.242

3.  Metabolic modeling predicts metabolite changes in Mycobacterium tuberculosis.

Authors:  Christopher D Garay; Jonathan M Dreyfuss; James E Galagan
Journal:  BMC Syst Biol       Date:  2015-09-16

4.  Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.

Authors:  Shashikant Srivastava
Journal:  Lung India       Date:  2015 Jul-Aug

Review 5.  Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Authors:  Thomas J Hwang; Svetlana Dotsenko; Azizkhon Jafarov; Karin Weyer; Dennis Falzon; Kaspars Lunte; Paul Nunn; Ernesto Jaramillo; Salmaan Keshavjee; Douglas F Wares
Journal:  BMJ Open       Date:  2014-01-02       Impact factor: 2.692

6.  Assessing the utility of contact tracing in reducing the magnitude of tuberculosis.

Authors:  Saurabh R Shrivastava; Prateek S Shrivastava; Jegadeesh Ramasamy
Journal:  Infect Ecol Epidemiol       Date:  2014-10-23

7.  Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy.

Authors:  Sultan Tousif; Dhiraj Kumar Singh; Sitabja Mukherjee; Shaheer Ahmad; Rakesh Arya; Ranjan Nanda; Anand Ranganathan; Maitree Bhattacharyya; Luc Van Kaer; Santosh K Kar; Gobardhan Das
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

8.  Structural basis for the in vitro known acyl-depsipeptide 2 (ADEP2) inhibition to Clp 2 protease from Mycobacterium tuberculosis.

Authors:  Natasha Khandekar; Snehal Singh; Ruchi Shukla; Sridevi Tirumalaraju; Srinivas Bandaru; Tushar Banerjee; Anuraj Nayarisseri
Journal:  Bioinformation       Date:  2016-06-21

9.  Ending tuberculosis in India: A political challenge & an opportunity.

Authors:  Hannah Monica Yesudian Dias; Madhukar Pai; Mario C Raviglione
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

Review 10.  Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.

Authors:  Ashley L Biecker; Xiaodong Liu; Jon S Thorson; Zhaoyong Yang; Steven G Van Lanen
Journal:  Molecules       Date:  2019-01-25       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.